Pasar al contenido principal

PAPEL DE LOS REGULADORES DEL CICLO CELULAR E2F1 Y E2F2 EN LA PATOGENESIS Y PRONOSTICO DE LA ENFERMEDAD HEPATICA: DE HEPATOESTEATOSIS A HEPATOCARCINOMA

SAF2015-64352-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

  • Porteiro Couto, Begoña
  • Fernández Fondevila, Marcos
  • Buque García, Xabier
  • González Rellán, María Jesús
  • Fernández Paz, Uxía
  • Mora Corral, Alfonso
  • Beiroa Tarrío, Daniel
  • Senra, Ana
  • Gallego Gómez, Rosalía
  • Fernø, Johan
  • López Pérez, Miguel A.
  • Sabio, Guadalupe
  • García Diéguez, Carlos
  • Aspichueta Celaá, Patricia
  • Nogueiras Pozo, Rubén
Objective Recent reports have implicated the p53 tumor suppressor in the regulation of lipid metabolism. We hypothesized that the pharmacological activation of p53 with low-dose doxorubicin, which is widely used to treat several types of cancer, may have beneficial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Methods We used long-term pharmacological activation of p53 by i.p. or oral administration of low-dose doxorubicin in different animal models of NAFLD (high fat diet containing 45% and 60% kcal fat) and NASH (methionine- and choline-deficient diet and choline deficiency combined with high fat diet). We also administered doxorubicin in mice lacking p53 in the liver and in two human hepatic cells lines (HepG2 and THLE2). Results The attenuation of liver damage was accompanied by the stimulation of fatty acid oxidation and decrease of lipogenesis, inflammation, and ER stress. The effects of doxorubicin were abrogated in mice with liver-specific ablation of p53. Finally, the effects of doxorubicin on lipid metabolism found in animal models were also present in two human hepatic cells lines, in which the drug stimulated fatty acid oxidation and inhibited de novo lipogenesis at doses that did not cause changes in apoptosis or cell viability. Conclusion These data provide new evidence for targeting p53 as a strategy to treat liver disease
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Hypothalamic AMPK-ER Stress-JNK1 axis mediates the central actions of thyroid hormones on energy balance

  • Martinez-Sanchez, Noelia
  • Seoane-Collazo, Patricia
  • Contreras, Cristina
  • Varela, Luis
  • Villarroya, Joan
  • Rial-Pensado, Eva
  • Buque, Xabier
  • Aurrekoetxea, Igor
  • Delgado, Teresa C.
  • Vazquez-Martinez, Rafael
  • Gonzalez-Garcia, Ismael
  • Roa, Juan
  • Whittle, Andrew J.
  • Gomez-Santos, Beatriz
  • Velagapudi, Vidya
  • Loraine Tung, Y. C.
  • Morgan, Donald A.
  • Voshol, Peter J.
  • Martinez de Morentin, Pablo B.
  • Lopez-Gonzalez, Tania
  • Linares-Pose, Laura
  • Gonzalez, Francisco
  • Chatterjee, Krishna
  • Sobrino, Tomas
  • Medina-Gomez, Gema
  • Davis, Roger J.
  • Casals i Farré, Núria
  • Oresic, Matej
  • Coll, Anthony P.
  • Vidal-Puig, Antonio
  • Mittag, Jens
  • Tena-Sempere, Manuel
  • Malagon, Maria M.
  • Dieguez, Carlos
  • Martinez-Chantar, Maria Luz
  • Aspichueta, Patricia
  • Rahmouni, Kamal
  • Nogueiras, Rubén
  • Sabio, Guadalupe
  • Villarroya, Francesc
  • Lopez, Miguel
We dedicate this work to the bright memory of our colleague and friend Rafael Vazquez-Martınez. The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreements n260464 – the OBECAN project (G.S.) and n 281854 – the ObERStress project (M.L.), Xunta de Galicia (F.G., ED431C2016-025 and ED341D-R2016-032; R.N., 2015-CP080 and 2016-PG057; M.L., 2015-CP079 and 2016-PG068), Junta de Andalucı´a (M.T.-S., P12-FQM-01943), Gobierno Vasco-Departamento de Salud (M.L.M.-C., 2013111114), EITB (M.L.M.-C., BIO15/CA/014), Ayudas para apoyar grupos de investigacion del sistema Universitario Vasco (P.A., IT971-16), Generalitat de Catalunya (N.C., 2014SGR465), Fundacio´ La Marato´ de TV3 (N.C., 87/C/2016), Instituto de Salud Carlos III co-funded by FEDER (F.G., RD16/0008/0003; M.L.M.-C., PIE14/00031), Ministerio de Economı´a y Competitividad (MINECO) co-funded by the FEDER Program of EU (N.C., SAF2014-52223-C2-2-R; M.T.-S., BFU2014-57581-P -P; M.M.M., BFU2013-44229-R; C.D., BFU2014-55871-P; M.L.M.-C., SAF2014-54658-R; P.A., SAF2015-64352-R; R.N., BFU2015-70664R; G.S., SAF2013-43506-R; F.V., SAF2014 55725; M.L., SAF2015-71026-R; G.M., M.M.M., F.V., and M.L., BFU2015-70454-REDT/Adipoplast), Asociacio´ n Espan˜ ola contra el Ca´ ncer (T.C.D. and M.L.M.-C.), Medical Research Council (MRC) Metabolic Diseases Unit (A.J.W., Y.C.L.T., A.P.C., and A.V.-P., MRC_MC_UU_12012/1 and MRC_UU_12015/5), MRC Programme Grant (Y.C.L.T. and A.P.C., G9824984), MRC Disease Model Core (P.J.V. and A.V.-P.), Wellcome Trust Investigator Award (K.C., 095564/Z/11/Z), Deutsche Forschungsgemeinschaft (J.M., Mi1242/2-1), NIH (R.J.D., DK107220 and DK112698; K.R., HL084207), American Heart Association (K.R., EIA#14EIA18860041) and the University of Iowa Fraternal Order of Eagles Diabetes Research Center (K.R.), EFSD/Lilly Programme (G.S., GIM/EFS1601), Astra Zeneca Foundation (R.N.) and the European Foundation for the Study of Diabetes (R.N.), and Atresmedia Corporacion (M.L.). C.C. is recipient of a Sara Borrell Contract (CD14/0007) from ISCIII; J.V. is recipient of a Juan de la Cierva Contract (IJDC-2014-19681) from MINECO; E.R.-P. is recipient of a fellowship from MINECO (BES-2015-072743); I.G.-G. is recipient of a fellowship from MINECO (FPU12/01827); L.L.-P. is recipient of a fellowship from Xunta de Galicia (ED481A-2016/094); T.C.D. is supported by AECC (AIO2013); T.S. is recipient of a Miguel Servet Contract (CP12/03121) from ISCIII; R.J.D. is an Investigator of the Howard Hughes Medical Institute; and F.V. is an ICREA Academia researcher, Generalitat de Catalunya. The CiMUS is supported by the Xunta de Galicia (2016–2019, ED431G/05) and the CNIC is supported by the MINECO and the Pro-CNIC Foundation. Pro-CNIC Foundation is a Severo Ochoa Center of Excellence (MINECO award SEV2015-0505). The technical assistance of Luz Casas in performing the in situ hybridization, Maria Jesus Sanchez-Tapia in performing genotyping analyses, and Tuulikki Seppanen-Laakso and Ulla Lahtinen in performing lipidomics ana- €lyses is cordially appreciated. CIBER de Fisiopatologı´a de la Obesidad y Nutricio´ n and CIBER de Enfermedades hepa´ticas y Digestivas are initiatives of ISCIII. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Thyroid hormones (THs) act in the brain to modulate energy balance. We show that central triiodothyronine (T3) regulates de novo lipogenesis in liver and lipid oxidation in brown adipose tissue (BAT) through the parasympathetic (PSNS) and sympathetic nervous system (SNS), respectively. Central T3 promotes hepatic lipogenesis with parallel stimulation of the thermogenic program in BAT. The action of T3 depends on AMP-activated protein kinase (AMPK)-induced regulation of two signaling pathways in the ventromedial nucleus of the hypothalamus (VMH): decreased ceramide-induced endoplasmic reticulum(ER) stress, which promotes BAT thermogenesis, and increased c-Jun N-terminal kinase (JNK) activation, which controls hepatic lipid metabolism. Of note, ablation of AMPK alpha 1 in steroidogenic factor 1 (SF1) neurons of the VMH fully recapitulated the effect of central T3, pointing to this population in mediating the effect of central THs on metabolism. Overall, these findings uncover the underlying pathways through which central T3 modulates peripheral metabolism., info:eu-repo/semantics/acceptedVersion